Imatinib-Induced Acquired Dermal Melanocytosis
Main Article Content
Keywords
Imatinib, Hyperpigmentation, Dermal Melanocytosis, BCR-ABL Inhibitor
Abstract
Background: Imatinib, a tyrosine kinase inhibitor targeting bcr-abl, c-Kit, and PDGF receptors-alpha and beta, is commonly used to treat GI stromal tumors and hematologic malignancies. Hyperpigmentation is a known side-effect of imatinib, with intradermal hemosiderosis being the most common histologic finding.
Case Presentation: We report a rare case of concurrent hypopigmentation and hyperpigmentation secondary to dermal melanocytosis following imatinib treatment in an African American patient with acute lymphoblastic leukemia.
Conclusion: Early referral to dermatology in patients with similar findings is appropriate given the increased risk of melanoma conferred by heightened melanocyte proliferation.
References
2. Scheinfeld N. Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate. J Drugs Dermatol 2006;5:228–231.
3. Arora B, Kumar L, Sharma A, Wadhwa J, Kochupillai V. Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate. Ann Oncol 2004;15:358-9.
4. Pureesrisak P, Tienthavorn T. Imatinib mesylate induced acquired dermal melanocytosis: a rare case report. Thai Journal of Dermatology. 2017; 33(4): 297-305.
5. Grichnik JM, Burch JA, Burchette J, Shea CR. The SCF/KIT pathway plays a critical role in the control of normal human melanocyte homeostasis. J Invest Dermatol 1998;111:233-8.
6. Maiti B, Setrakian S, Daw HA. Hepatic iron overload, a possible consequence of treatment with imatinib mesylate: a case report. Cases J. 2009; 2:7526.
7. Kok WL, Chen Q, Lee SSJ, Chua SH, Ng SK. A case series of imatinib-induced generalized hypopigmentation and progression of existing acquired dermal melanocytosis. J Dermatolog Treat. 2017;28(8):762–3.
8. Baykal C, Yılmaz Z, Sun GP, Büyükbabani N. The spectrum of benign dermal dendritic melanocytic proliferations. J Eur Acad Dermatol Venereol. 2019;33(6):1029-1041.
9. Tse JY, Walls BE, Pomerantz H, Yoon CH, et al. Melanoma arising in a nevus of Ito: novel genetic mutations and a review of the literature on cutaneous malignant transformation of dermal melanocytosis. J Cutan Pathol. 2016;43(1):57-63.
10. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006;24(26):4340-6.
11. Hodi FS, Corless CL, Giobbie-Hurder A, et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013;31(26):3182-90.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.